BioCentury | Oct 21, 2020
Deals

Oct. 21 Quick Takes: Clear path for BMS in MyoKardia deal; plus WuXi Biologics rises, Purdue settles, Actemra, Cara-Vifor and more

...financing.Setback at FDA sinks Zosano stockShares of Zosano Pharma Corp....
...505(b)(2) pathway. BC Staff OxyContin, oxycodone MyoKardia Inc. Purdue Pharma L.P. Cara Therapeutics InCarda Azitra Zosano Leaps...
BioCentury | Oct 8, 2019
Company News

Oct. 8 Company Quick Takes: Novartis’ anti-VEGF approved for AMD; plus Merck-4D, Acorda, Clinuvel and Puma

...chief commercial officer, effective Oct. 18, to accept a position as president and CEO of Zosano Pharma Corp....
BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

...plc (NASDAQ:AUTL) 4/10/19 $115.9 $1,079.4 $724.1 -33% PolarityTE Inc. (NASDAQ:PTE) 4/10/19 $29.1 $213.7 $140.9 -34% Zosano Pharma Corp....
BioCentury | Jun 29, 2019
Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

...patients who are ineligble for high-dose chemotherapy and autologous stem cell transplantation Submit BLA YE19 Zosano Pharma Corp....
BioCentury | Jan 5, 2019
Finance

Ready to launch

...lymphoma Submit BLA 2H19 Zogenix Inc. (NASDAQ:ZGNX) Fintepla (ZX008) Dravet syndrome Complete rolling NDA 1Q19 Zosano Pharma Corp....
BioCentury | Oct 30, 2018
Company News

Management tracks: Blueprint, Clovis

...and promoted SVP of Research Holger Wesche to CSO. Erbez was CBO and CFO of Zosano Pharma Corp....
BioCentury | Mar 30, 2018
Financial News

Zosano raises $50M in follow-on

...Drug delivery company Zosano Pharma Corp. (NASDAQ:ZSAN) raised $50 million on March 29 through the sale of 10...
...Applied Microarray technology for the rapid systemic administration of therapeutics. Zosano Pharma Corp. (NASDAQ:ZSAN), Fremont, Calif. Elizabeth S. Eaton Zosano Pharma Corp....
BioCentury | May 10, 2017
Company News

Management tracks

...manager of the genomics and clinical applications division of Agilent Technologies Inc. (NYSE:A). Neurology company Zosano Pharma Corp....
BioCentury | Apr 13, 2017
Clinical News

M207: Ph II/III Zotrip data

...10.4%, p=0.0084); 24 hours (69.5% vs. 39%, p=0.0001); and 48 hours (64.6% vs. 39%, p=0.0013). Zosano...
...met the pain freedom co-primary endpoint, but missed the most bothersome other symptom co-primary endpoint. Zosano...
...for the 2 lower doses. M207 was well tolerated with no serious adverse events reported. Zosano...
BioCentury | Apr 7, 2017
Finance

Taking notice

...Inc. (NASDAQ:AXSM) 3/21/17 $16.1 $87.9 $91.7 4% RegenxBio Inc. (NASDAQ:RGNX) 3/21/17 $75.9 $619.4 $583.1 -6% Zosano Pharma Corp....
Items per page:
1 - 10 of 72
BioCentury | Oct 21, 2020
Deals

Oct. 21 Quick Takes: Clear path for BMS in MyoKardia deal; plus WuXi Biologics rises, Purdue settles, Actemra, Cara-Vifor and more

...financing.Setback at FDA sinks Zosano stockShares of Zosano Pharma Corp....
...505(b)(2) pathway. BC Staff OxyContin, oxycodone MyoKardia Inc. Purdue Pharma L.P. Cara Therapeutics InCarda Azitra Zosano Leaps...
BioCentury | Oct 8, 2019
Company News

Oct. 8 Company Quick Takes: Novartis’ anti-VEGF approved for AMD; plus Merck-4D, Acorda, Clinuvel and Puma

...chief commercial officer, effective Oct. 18, to accept a position as president and CEO of Zosano Pharma Corp....
BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

...plc (NASDAQ:AUTL) 4/10/19 $115.9 $1,079.4 $724.1 -33% PolarityTE Inc. (NASDAQ:PTE) 4/10/19 $29.1 $213.7 $140.9 -34% Zosano Pharma Corp....
BioCentury | Jun 29, 2019
Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

...patients who are ineligble for high-dose chemotherapy and autologous stem cell transplantation Submit BLA YE19 Zosano Pharma Corp....
BioCentury | Jan 5, 2019
Finance

Ready to launch

...lymphoma Submit BLA 2H19 Zogenix Inc. (NASDAQ:ZGNX) Fintepla (ZX008) Dravet syndrome Complete rolling NDA 1Q19 Zosano Pharma Corp....
BioCentury | Oct 30, 2018
Company News

Management tracks: Blueprint, Clovis

...and promoted SVP of Research Holger Wesche to CSO. Erbez was CBO and CFO of Zosano Pharma Corp....
BioCentury | Mar 30, 2018
Financial News

Zosano raises $50M in follow-on

...Drug delivery company Zosano Pharma Corp. (NASDAQ:ZSAN) raised $50 million on March 29 through the sale of 10...
...Applied Microarray technology for the rapid systemic administration of therapeutics. Zosano Pharma Corp. (NASDAQ:ZSAN), Fremont, Calif. Elizabeth S. Eaton Zosano Pharma Corp....
BioCentury | May 10, 2017
Company News

Management tracks

...manager of the genomics and clinical applications division of Agilent Technologies Inc. (NYSE:A). Neurology company Zosano Pharma Corp....
BioCentury | Apr 13, 2017
Clinical News

M207: Ph II/III Zotrip data

...10.4%, p=0.0084); 24 hours (69.5% vs. 39%, p=0.0001); and 48 hours (64.6% vs. 39%, p=0.0013). Zosano...
...met the pain freedom co-primary endpoint, but missed the most bothersome other symptom co-primary endpoint. Zosano...
...for the 2 lower doses. M207 was well tolerated with no serious adverse events reported. Zosano...
BioCentury | Apr 7, 2017
Finance

Taking notice

...Inc. (NASDAQ:AXSM) 3/21/17 $16.1 $87.9 $91.7 4% RegenxBio Inc. (NASDAQ:RGNX) 3/21/17 $75.9 $619.4 $583.1 -6% Zosano Pharma Corp....
Items per page:
1 - 10 of 72